Daniel Loeb's BHC Position Overview
Daniel Loeb (via Third Point LLC) currently holds 350,000 shares of Bausch Health Companies Inc. (BHC) worth $2.43 M, representing 0.03% of the portfolio. First purchased in 2014-Q1, this short-term holding has been held for 4 quarters.
Based on 13F filings, Daniel Loeb has maintained this position in BHC for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 250,000 shares. Largest reduction occurred in Q2 2014, reducing 250,000 shares.
Analysis based on 13F filings available since 2013 Q2
Daniel Loeb's Bausch Health Companies (BHC) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bausch Health Companies (BHC) Trades by Daniel Loeb
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +250,000 | Add 250.00% | 350,000 | $6.95 |
| Q3 2025 | +100,000 | New Buy | 100,000 | $6.45 |
| Q2 2014 | -250,000 | Sold Out | 0 | $0.00 |
| Q1 2014 | +250,000 | New Buy | 250,000 | $131.83 |
Daniel Loeb's Bausch Health Companies Investment FAQs
Daniel Loeb first purchased Bausch Health Companies Inc. (BHC) in Q1 2014, acquiring 250,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Daniel Loeb has held Bausch Health Companies Inc. (BHC) for 4 quarters since Q1 2014.
Daniel Loeb's largest addition to Bausch Health Companies Inc. (BHC) was in Q1 2014, adding 250,000 shares worth $32.96 M.
According to the latest 13F filing for Q4 2025, Daniel Loeb's firm, Third Point LLC, owns 350,000 shares of Bausch Health Companies Inc. (BHC), valued at approximately $2.43 M.
As of the Q4 2025 filing, Bausch Health Companies Inc. (BHC) represents approximately 0.03% of Daniel Loeb's publicly disclosed stock portfolio, making it one of their key holdings.
Daniel Loeb's peak holding in Bausch Health Companies Inc. (BHC) was 350,000 shares, as reported at the end of Q4 2025.